Bayer (FRA:BAYN) Given a €110.00 Price Target at UBS Group

UBS Group set a €110.00 ($127.91) target price on Bayer (FRA:BAYN) in a report published on Tuesday, Borsen Zeitung reports. The firm currently has a buy rating on the healthcare company’s stock.

Several other brokerages also recently issued reports on BAYN. JPMorgan Chase & Co. reiterated a sell rating and issued a $18.00 price target on shares of ABB in a report on Monday. Barclays increased their price target on Intuit from $225.00 to $237.00 and gave the company an equal weight rating in a report on Friday, May 24th. DZ Bank upgraded Telefonica from a hold rating to a buy rating in a report on Tuesday, May 14th. Deutsche Bank decreased their price objective on shares of Xilinx from $125.00 to $120.00 and set a hold rating for the company in a research report on Thursday, April 25th. Finally, Berenberg Bank reissued a hold rating and issued a GBX 1,581 ($20.66) price objective on shares of in a research report on Tuesday, June 11th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and twelve have issued a buy rating to the stock. Bayer currently has an average rating of Hold and an average price target of €80.67 ($93.81).

Shares of FRA BAYN opened at €59.96 ($69.72) on Tuesday. Bayer has a 12-month low of €91.58 ($106.49) and a 12-month high of €123.82 ($143.98). The firm has a fifty day moving average of €56.55.

About Bayer

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Recommended Story: How Do You Make Money With Penny Stocks?

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with's FREE daily email newsletter.